Trevena (NASDAQ:TRVN) coverage was initiated by analysts at StockNews.com

StockNews.com has assumed coverage of the stock of Trevena (NASDAQ:TRVN – Free Report) in a report issued on Saturday. The firm has issued a sell rating on the biopharmaceutical company’s stock.

Trevena share performance

TRVN opened at $4.01 on Friday. Trevena has a one year low of $3.35 and a one year high of $25.75. The company has a market cap of $73.55 million, a P/E ratio of -1.50 and a beta of 1.03. The company’s 50-day simple moving average is $2.72 and its 200-day simple moving average is $1.20.

Trevena (NASDAQ:TRVN – Get Your Free Report ) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.36. The company had revenue of $0.33 million during the quarter.

Hedge funds are weighing on Trevena

An institutional investor recently bought a new position in shares of Trevena. Armistice Capital LLC bought a new stake in Trevena, Inc. (NASDAQ:TRVN – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena as of its most recent SEC filing. Institutional investors own 13.56% of the company’s shares.

About Trevena

(Get a free report)

Trevena, Inc, a biopharmaceutical company, focuses on developing and commercializing new medicines for patients affected by disorders of the central nervous system. Its lead candidates include OLINVYK (Olyceridine) injection, a G protein-biased mu-opioid receptor (MOR) ligand for the management of moderate to severe acute pain; TRV250, a G-protein delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein ligand of MOR for the treatment of moderate to severe acute and chronic pain; and TRV045, a novel S1P modulator for chronic pain management.

See Also

Get news and reviews for Trevena Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Trevena and related companies with MarketBeat.com’s FREE daily email newsletter.